Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology†
by
Christine Rangger and Roland Haubner *
Christine Rangger and Roland Haubner *
Department of Nuclear Medicine, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria
*
Author to whom correspondence should be addressed.
†
This paper is dedicated to the 80th birthday of Prof. Horst Kessler.
Pharmaceuticals 2020, 13(2), 22; https://doi.org/10.3390/ph13020022
Received: 20 December 2019 / Revised: 14 January 2020 / Accepted: 16 January 2020 / Published: 30 January 2020
(This article belongs to the Special Issue The Future Direction of Radiopharmaceutical Development for Cancer Theranostics)
This review deals with the development of peptide-based radiopharmaceuticals for the use with positron emission tomography and peptide receptor radiotherapy. It discusses the pros and cons of this class of radiopharmaceuticals as well as the different labelling strategies, and summarises approaches to optimise metabolic stability. Additionally, it presents different target structures and addresses corresponding tracers, which are already used in clinical routine or are being investigated in clinical trials.
Keywords:
radiolabelled peptides; positron emission tomography; peptide receptor radiotherapy; oncology; metabolic stability; labelling strategies
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Rangger, C.; Haubner, R. Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology. Pharmaceuticals 2020, 13, 22.
Show more citation formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
